Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Toronto, Ontario–(Newsfile Corp. – September 24, 2024) – Cardiol Therapeutics Inc. (NASDAQ:…

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Full clinical data will be reported in an oral presentation at the…

Clearmind Medicine Granted Patent Approval in Hong Kong

Vancouver, Canada, June 28, 2024  — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind”…

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Administration of CardiolRx™ led to a marked reduction in the primary efficacy…

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Scope of presentation included trial design, rationale, and blinded baseline data on…

Treatment.com AI and Novus Health Partnership Expands Access to its Global Library of Medicine (GLM)

VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) — Treatment.com AI Inc.…